Investors in Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA

1. Sana Biotechnology faces class action over misleading financial statements. 2. Allegations include insufficient cash flow for ongoing projects. 3. Possible discontinuation of crucial product candidates SC291, SC379, SG299. 4. Deadline for lead plaintiff registration is May 20, 2025. 5. Firm claims defendants overstated financial health of the company.

Legal

95

5m saved

Insight

Article

FAQ

Why Very Bearish?

Allegations of misleading statements and financial mismanagement significantly harm investor confidence.

How important is it?

The class-action lawsuit revolves around critical accusations affecting SANA’s operational viability and financial integrity.

Why Long Term?

The outcome of legal proceedings and its implications on operations may affect SANA long-term.

Related Companies

NASDAQ: SANA NASDAQ: CRIS NASDAQ: NVTA NYSE: RHHBY

NEW YORK, May 15, 2025 /PRNewswire/ --

The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).

Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=148423&from=4

CLASS PERIOD:

March 17, 2023 to November 4, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:

(i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates;
(ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe;
(iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount;
(iv) accordingly, defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates;
(v) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

DEADLINE:

May 20, 2025

Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=148423&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of SANA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 20, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm

15 West 38th Street, 12th floor
New York, NY, 10018

Email: info@grosslawfirm.com

Phone: (646) 453-8903

SOURCE The Gross Law Firm